Cure Pharmaceutical (OTC:CURR) announced today that it received confirmation of a patent for its Curefilm Blue platform.\
The U.S. Patent Office (USPTO) provided notification to Cure that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ‘331 patent (“Oral Soluble Film Containing Sildenafil Citrate”) covers Curefilm blue.
Oxnard, California-based Cure Pharmaceutical designed Curefilm Blue as an oral soluble film of sildenafil citrate (the active ingredient present in Viagra) for treating erectile dysfunction (ED). The company is seeking approval of the product via the FDA 505(b)(2) regulatory pathway, according to a news release.
Curefilm Blue uses Cure’s patented and proprietary Curefilm fast-dissolving drug delivery platform to deliver the active pharmaceutical ingredient sildenafil citrate, offering a convenient and portable oral film product to replace pills and other delivery methods for a better patient experience.
The company said the ‘331 patent includes a balance of performance characteristics (fast-dissolving and early onset of action) and physical parameters (large mass, small thickness), while Curefilm blue can be administered without water or beverage.
